MA, Part D Plans Face New Premium Calculus With Drug Price Negotiation

  • Jan 20, 2023

    The coming year is unlikely to see any major new policy developments come out of the split Congress, but health insurers and other stakeholders will have their hands full figuring out the implications of the Inflation Reduction Act’s (IRA) Medicare drug price negotiation policy, according to a Jan. 18 panel of Avalere Health experts. 

    Last November’s election led to divided control of Congress, with Republicans in control of the House of Representatives and Democrats in control of the Senate. Given that, “the activity this year, over the next two years, is going to look quite a bit different than we saw in Congress from the previous two years,” said Matt Kazan, managing director at Avalere.  

    Read more
  • Peter Johnson

    Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

The Latest
Meet Our Reporters

Meet Our Reporters

×
×